EntreMed, Inc.

Pharma company announces patents for 2- methoxyestradiol and its derivatives

Published in Pharma Law Weekly, September 13th, 2005

EntreMed, Inc., (ENMD) announced the issuance of two U.S. patents covering its lead clinical-stage compound, 2- methoxyestradiol (2ME2) and multiple derivatives of 2ME2.

2ME2 (Panzem Capsules and Panzem NCD) is currently in clinical trials for cancer, as well as in preclinical development for inflammatory disorders.

The patents grant EntreMed intellectual property protection for 2ME2 and derivatives of 2ME2 in oncology and a broad range of nononcology indications, including inflammatory disorders, immune disorders, cardiovascular disorders, and rheumatoid arthritis.

2ME2 is a novel anticancer agent, which is part of a next...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2005-09-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry